Dr Reddy’s Takes Another Step Forward On Tocilizumab
IV Version Of Indian Firm’s Actemra/RoActemra Biosimilar Completes Phase I Study
Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.
You may also be interested in...
Fresenius Kabi has celebrated the approval of Europe’s first tocilizumab biosimilar. The rival to RoActemra is expected to be launched later this year under a settlement agreement with originator Genentech.
With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.
Dr Reddy’s has celebrated a “milestone” for its biosimilars business after disclosing that multiple regulators in Europe and the US have accepted its rituximab filings for review.